<SEC-DOCUMENT>0001683168-18-003562.txt : 20181127
<SEC-HEADER>0001683168-18-003562.hdr.sgml : 20181127
<ACCEPTANCE-DATETIME>20181127073012
ACCESSION NUMBER:		0001683168-18-003562
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181127
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181127
DATE AS OF CHANGE:		20181127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		181201963

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to
Section 13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
November 27, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">001-37487</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Form 8-K and other reports filed by Registrant from time
to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may contain forward-looking
statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well
as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo; &quot;believe,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Registrant believes that the expectations reflected
in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On November 27, 2018, Aethlon Medical,
Inc. released the press release attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626"><B>ITEM 9.01 Financial
Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #262626">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aethlon_8k-ex9901.htm">Press Release, dated November 27, 2018</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;<U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 27, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Aethlon
Medical&rsquo;s Cancer Therapy Receives &ldquo;Breakthrough Device&rdquo; Designation from the U.S. Food and Drug Administration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, CA, November 27, 2018 -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it
has received a &ldquo;Breakthrough Device&rdquo; designation from the U.S. Food and Drug Administration (FDA) to support the advancement
of the Aethlon Hemopurifier&reg; for the treatment of cancer. The Aethlon Hemopurifier is a first-in-class technology designed
for the rapid depletion of cancer-promoting exosomes and life-threatening viruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA&rsquo;s Breakthrough Device program
was established under the 21<SUP>st</SUP> Century Cures Act to facilitate more rapid patient access to breakthrough technologies
with the potential to&nbsp;address life threatening disease conditions for which no approved or cleared treatment alternatives&nbsp;exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are honored to receive this breakthrough
designation in oncology as it establishes an opportunity to expand the market for our Hemopurifier and advance our vision for addressing
a significant unmet need in cancer care,&rdquo; stated Aethlon Medical founder and CEO, Jim Joyce. &ldquo;By reducing the presence
of tumor-derived exosomes from the circulatory system of cancer patients, we believe our Hemopurifier can improve the benefit of
existing cancer treatment regimens and emerging immuno-oncology drugs. Thus providing a rationale for potential partnering opportunities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262626">Cancer
is the second leading cause of death globally and is estimated to account for 9.6 million deaths in 2018 (Source: World Health
Organization).&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor-derived exosomes, which
are not addressed with an approved therapy, have been discovered to promote immune suppression, seed the spread of metastasis and
inhibit the benefit of many leading cancer therapies. Aethlon has recently demonstrated the ability of the Hemopurifier to capture
exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma. To learn more about the Hemopurifier
in cancer, click here: </FONT>https://tinyurl.com/Aethlon-White-Paper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed indications for use (IFU)
under the Breakthrough Device designation includes, &quot;The Hemopurifier is a single-use device indicated for the treatment of
individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in the development or severity of the disease. Therapy with the Hemopurifier
device should be an adjunct to standard of care for cancer.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon is also advancing the Hemopurifier
as a candidate to treat life-threatening viruses. In this regard, the Hemopurifier was designated as a Breakthrough Device indicated
for the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical is focused on addressing unmet needs in global
health. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression,
seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier is also an FDA designated &quot;Breakthrough
Device&quot; related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additionally,
Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.
You can also connect with us on Twitter, LinkedIn and Facebook.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; or
similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq
Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize
its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market
clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the
development of its planned products, the Company's ability to manufacture its products either internally or through outside companies,
the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty
of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties
is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated
in forward-looking statements can be found under the caption &quot;Risk Factors&quot; in the Company's Annual Report on Form 10-K
for the year ended March 31, 2018, and in the Company's other filings with the Securities and Exchange Commission. Except as may
be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events
or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 extension 3300</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> /4# 2(  A$! Q$!_\0
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MWQ#T[Q$R6LP^QWYZ0NV5<_[+=_IUKSL1EM:@N;==T=5+%TZCMLSLJ*0'-+7
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MUWHNH21_(Y(5XW;8<KT#J><CKQZXKO/VA_\ DF\'_81B_P#0'H [?P%-+<>
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M<7EP^R"WC:61O15&2?R%>*:=XX\?_$_4;E/"2VNB:/ ^Q[R=0[^H&2#EL<X
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M\0Z;I[[O.3PZULTV#M60DCK[5>\):_9Z'H5EH>HVUU9ZA;_N6B^S.P=L_>#
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=UP5\76K_ ,1Z=NATTJ%.E\*"BBBN8V"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
